Keith Powell

Intract Pharma Ltd. is a British biotechnology company that focuses on developing oral biologics delivery solutions to improve the efficacy and safety of biotherapeutics. The private company is based in London, UK. The company's platform delivers large proteins and antibodies to the colon while protecting them from enzymatic breakdown, allowing for tissue and systemic uptake. This approach aims to replace injections with safer and more effective oral therapeutics, ultimately improving patient experience and outcomes. The company was founded in 2015 by William Pirie Lindsay, Syed Abdul Waseh Basit. Vipul Yadav has been the CEO of the company since 2022.

Intract Pharma Ltd. is a British biotechnology company that focuses on developing oral biologics delivery solutions to improve the efficacy and safety of biotherapeutics. The private company is based in London, UK. The company's platform delivers large proteins and antibodies to the colon while protecting them from enzymatic breakdown, allowing for tissue and systemic uptake. This approach aims to replace injections with safer and more effective oral therapeutics, ultimately improving patient experience and outcomes. The company was founded in 2015 by William Pirie Lindsay, Syed Abdul Waseh Basit. Vipul Yadav has been the CEO of the company since 2022.

Intract Pharma Ltd. is a British biotechnology company that focuses on developing oral biologics delivery solutions to improve the efficacy and safety of biotherapeutics. The private company is based in London, UK. The company's platform delivers large proteins and antibodies to the colon while protecting them from enzymatic breakdown, allowing for tissue and systemic uptake. This approach aims to replace injections with safer and more effective oral therapeutics, ultimately improving patient experience and outcomes. The company was founded in 2015 by William Pirie Lindsay, Syed Abdul Waseh Basit. Vipul Yadav has been the CEO of the company since 2022.